Literature DB >> 18614793

Duration of survival in patients with myeloma treated with thalidomide.

Bart Barlogie, John D Shaughnessy, John Crowley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18614793     DOI： 10.1056/NEJMc0801352

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

Authors:  Amrita Krishnan; Marcelo C Pasquini; Brent Logan; Edward A Stadtmauer; David H Vesole; Edwin Alyea; Joseph H Antin; Raymond Comenzo; Stacey Goodman; Parameswaran Hari; Ginna Laport; Muzaffar H Qazilbash; Scott Rowley; Firoozeh Sahebi; George Somlo; Dan T Vogl; Daniel Weisdorf; Marian Ewell; Juan Wu; Nancy L Geller; Mary M Horowitz; Sergio Giralt; David G Maloney
Journal:  Lancet Oncol       Date:  2011-09-29       Impact factor: 41.316

2.  First thalidomide clinical trial in multiple myeloma: a decade.

Authors:  Frits van Rhee; Madhav Dhodapkar; John D Shaughnessy; Elias Anaissie; David Siegel; Antje Hoering; Jerome Zeldis; Bonnie Jenkins; Seema Singhal; Jayesh Mehta; John Crowley; Sundar Jagannath; Bart Barlogie
Journal:  Blood       Date:  2008-05-23       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.